Array BioPharma is up 56% after agreeing to a sale to Pfizer for more than $10B. UniQuire, meanwhile, is higher by 8.35% after a weekend report thatit’s exploring a sale.
Other potential biotech targets: BioMarin (BMRN +4.2%), bluebird bio (BLUE+3.5%), Sage Therapeutics (SAGE +3%), Neurocrine Bio (NBIX +2.5%), Seattle Genetics (SGEN +4.8%), Sarepta (SRPT +1.5%).
The iShares Nasdaq Biotechnology ETF (IBB +2.9%)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.